13F Pro13F Pro

SEC Form 4 reporting owner

Akkaraju Srinivas

Akkaraju Srinivas has filed 30 Form 4 transactions reported between October 7, 2025 and October 26, 2026, as Director of Scholar Rock Holding Corp, a reporting owner of ALUMIS INC., Director of vTv Therapeutics Inc., a reporting owner of Kalaris Therapeutics, Inc. and Director of Mineralys Therapeutics, Inc..

Name as filed: AKKARAJU SRINIVAS

Follow Akkaraju Srinivas and get an alert on every new Form 4

Akkaraju Srinivas holds 7.1M shares of SRRK, worth $359.2M, 5.85% of the company.

As of their Oct 23, 2026 Form 4 (filed Oct 27, 2026) · the filing on SEC EDGAR · 27,971 direct, 7.1M indirect · valued at the Nov 19, 2026 close of $50.37 · 122.0M shares outstanding on Nov 6, 2026

Akkaraju Srinivas holds 7.2M shares of ALMS, worth $31.3M, 2.82% of the company.

As of their Sep 4, 2026 Form 4 (filed Sep 9, 2026) · the filing on SEC EDGAR · 3,553 direct, 7.2M indirect · valued at the Nov 19, 2026 close of $4.33 · 256.7M shares outstanding on Sep 30, 2026, weighted average, basic

Akkaraju Srinivas holds at least 2.2M shares of KLRS, worth $3.0M, 9.34% of the company.

As of their May 20, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $1.35 · 23.8M shares outstanding on Nov 3, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

Open-market buys, 24 mo
$37.6M
15 lines
Open-market sales, 24 mo
$1.0M
2 lines
Companies
5
with Form 4 filings
Latest transaction
Oct 26, 2026
transaction date

Roles and reported holdings

  • SRRKScholar Rock Holding Corp
    Oct 7, 2025 – Oct 26, 2026

    Director

    Held directly27,971 sh
    By Samsara BioCapital, L.P.6,380,517 sh
    By Samsara Opportunity Fund, L.P.723,020 sh

    As of Oct 23, 2026 · Form 4

    24 months: $13.2M bought

  • ALMSALUMIS INC.
    Jan 9, 2026 – Sep 8, 2026

    Reporting owner

    Held directly3,553 sh
    By Samsara BioCapital, L.P.4,937,026 sh
    By Samsara Opportunity Fund, L.P.2,298,783 sh

    Also reports 15,528 Stock Option (Right to Buy), not counted as shares.

    As of Sep 4, 2026 · Form 4

    Shares held, direct and indirect, ALMS, after each Form 4
    6.2M6.8M7.3MJun 30, 2026: 6.3M shares (Form 4)Sep 4, 2026: 7.2M shares (Form 4)Jun 30, 2026Sep 4, 2026
    FilingShares afterChange
    Sep 4, 20267.2M+891K
    Jun 30, 20266.3M—

    24 months: $18.3M bought · $1.0M sold

  • VTVTvTv Therapeutics Inc.
    Jun 26, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KLRSKalaris Therapeutics, Inc.
    Dec 18, 2025 – Jun 3, 2026

    Reporting owner

    Indirect (latest line that moved)2,224,147 sh

    As of May 20, 2026 · Form 4

    24 months: $6.2M bought

  • MLYSMineralys Therapeutics, Inc.
    Feb 19, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

How their buys did since

15 open-market purchases against today’s price: -14.0% on average, -39.1% weighted by dollars spent.

DatePaidReturn
Oct 26, 2026SRRK$41.59+21.1%now $50.37
Oct 26, 2026SRRK$41.59+21.1%now $50.37
Oct 23, 2026SRRK$41.82+20.4%now $50.37
Oct 23, 2026SRRK$41.82+20.4%now $50.37
Oct 23, 2026SRRK$41.31+21.9%now $50.37
Oct 23, 2026SRRK$41.31+21.9%now $50.37
Sep 8, 2026ALMS$10.63-59.3%now $4.33
Sep 8, 2026ALMS$10.63-59.3%now $4.33
Sep 4, 2026ALMS$11.17-61.3%now $4.33
May 20, 2026KLRS$4.83-72.0%now $1.35
Jan 9, 2026ALMS$17.00-74.5%now $4.33
Dec 18, 2025KLRS$10.42-87.0%now $1.35
Oct 7, 2025SRRK$40.97+22.9%now $50.37
Oct 7, 2025SRRK$40.18+25.4%now $50.37
Oct 7, 2025SRRK$39.31+28.1%now $50.37

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 30 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Oct 26, 2026SRRKOpen-market purchaseCode P · indirect97,982$4.1M@ $41.59Form 4
Oct 26, 2026SRRKOpen-market purchaseCode P · indirect48,988$2.0M@ $41.59Form 4
Oct 23, 2026SRRKOpen-market purchaseCode P · indirect1,000$42K@ $41.82Form 4
Oct 23, 2026SRRKOpen-market purchaseCode P · indirect500$21K@ $41.82Form 4
Oct 23, 2026SRRKOpen-market purchaseCode P · indirect94,000$3.9M@ $41.31Form 4
Oct 23, 2026SRRKOpen-market purchaseCode P · indirect47,000$1.9M@ $41.31Form 4
Sep 8, 2026ALMSOpen-market purchaseCode P · indirect273,290$2.9M@ $10.63Form 4
Sep 8, 2026ALMSOpen-market purchaseCode P · indirect273,291$2.9M@ $10.63Form 4
Sep 8, 2026ALMSOpen-market saleCode S · indirect48,065$507K@ $10.55Form 4
Sep 8, 2026ALMSOpen-market saleCode S · indirect48,066$507K@ $10.55Form 4
Sep 4, 2026ALMSOpen-market purchaseCode P · indirect220,070$2.5M@ $11.17Form 4
Jun 30, 2026ALMSGrant or awardCode A · direct15,528—Form 4
Jun 30, 2026ALMSGrant or awardCode A · direct3,553—Form 4
Jun 26, 2026VTVTDirectorGrant or awardCode A · direct6,000$210K@ $35.08Form 4
Jun 4, 2026SRRKDirectorGrant or awardCode A · direct4,310—Form 4
Jun 4, 2026SRRKDirectorGrant or awardCode A · direct6,839—Form 4
Jun 3, 2026KLRSGrant or awardCode A · direct9,000—Form 4
May 20, 2026KLRSOther acquisition or dispositionCode J · indirect4,471—Form 4
May 20, 2026KLRSOther acquisition or dispositionCode J · indirect14,937—Form 4
May 20, 2026KLRSOther acquisition or dispositionCode J · indirect66,906—Form 4
May 20, 2026KLRSOpen-market purchaseCode P · indirect244,300$1.2M@ $4.83Form 4
Feb 19, 2026MLYSDirectorGrant or awardCode A · direct8,300—Form 4
Feb 19, 2026MLYSDirectorGrant or awardCode A · direct6,200—Form 4
Jan 9, 2026ALMSOpen-market purchaseCode P · indirect588,235$10.0M@ $17.00Form 4
Dec 22, 2025KLRSGrant or awardCode A · indirect1,500,000$15.0M@ $10.00Form 4
Dec 18, 2025KLRSOpen-market purchaseCode P · indirect479,847$5.0M@ $10.42Form 4
Dec 12, 2025SRRKOption exerciseCode X · indirect1,064,804$7.8M@ $7.35Form 4
Oct 7, 2025SRRKOpen-market purchaseCode P · indirect4,403$180K@ $40.97Form 4
Oct 7, 2025SRRKOpen-market purchaseCode P · indirect12,400$498K@ $40.18Form 4
Oct 7, 2025SRRKOpen-market purchaseCode P · indirect12,796$503K@ $39.31Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.